How to transfer my Wegovy prescription to Florida

If you’ve been following the buzz around medications like Wegovy, Ozempic, and Mounjaro, you’ve probably wondered: Can I actually get these prescribed through telehealth? The short answer is yes—in most cases, you can legally obtain GLP-1 weight loss medications through legitimate online healthcare providers. But as with most things in healthcare, the details matter.

Let’s walk through everything you need to know about accessing these life-changing medications from the comfort of your home, including what’s legal, what’s safe, and how to navigate the process successfully.

Understanding GLP-1 Medications and Telehealth Access

GLP-1 receptor agonists—including semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound)—have revolutionized obesity treatment. These medications work by mimicking a natural hormone that regulates appetite and blood sugar, helping patients achieve significant weight loss when combined with lifestyle changes.

Here’s the good news for anyone considering telehealth: These medications are not controlled substances under federal law. This means they’re not subject to the strict DEA regulations that govern drugs like Adderall or opioids. The Ryan Haight Act, which typically requires an in-person visit before prescribing controlled medications via telehealth, doesn’t apply to GLP-1 drugs at all.

Federal Law Perspective

Under current federal regulations, healthcare providers can prescribe non-controlled medications like Wegovy and Ozempic through telehealth appointments without any mandated in-person examination. The COVID-19 pandemic accelerated telehealth adoption across all medical fields, and while some temporary flexibilities for controlled substances are set to expire on December 31, 2025, GLP-1 medications remain fully accessible via telemedicine regardless of these changes.

The DEA and HHS have extended telehealth flexibilities for controlled substances multiple times (most recently through the end of 2025), but this primarily affects medications for ADHD, pain management, and substance use disorders—not weight loss drugs.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Variations: What You Need to Know

While federal law is permissive, state regulations add another layer of complexity. Each state has its own medical board with specific rules about telehealth prescribing, provider qualifications, and standard of care requirements.

States Requiring Initial In-Person Visits

A handful of states mandate an in-person physical examination before or shortly after beginning weight loss medication treatment:

Arkansas has some of the strictest telehealth regulations in the country. The state requires an initial in-person exam to establish the patient-provider relationship before prescribing weight loss medications. However, follow-up appointments can be conducted via telehealth once that baseline is established.

Delaware similarly requires an initial physical examination in person, though subsequent monitoring visits may occur virtually.

Georgia recently updated its laws (effective July 2024) to allow nurse practitioners and physician assistants to prescribe Schedule II controlled substances with physician delegation—a significant expansion of prescriptive authority. However, the state still requires an initial in-person exam for obesity treatment medications as part of establishing appropriate care.

Mississippi maintains an in-person requirement for the first weight management evaluation, though this may change as the state considers legislation to expand NP practice authority.

New Jersey takes this further, requiring not just an in-person visit but a comprehensive evaluation including physical exam, laboratory work, psychological screening, and documentation of a personalized diet and exercise plan before prescribing any weight loss medication.

South Carolina and North Dakota also require initial in-person examinations before telehealth prescribing can begin.

Texas is worth special mention. While telehealth is broadly permitted, the standard of care typically expects an initial in-person assessment for weight loss treatment. Texas also has strict oversight of nurse practitioners and physician assistants—they must have formal physician agreements and cannot prescribe certain medications independently.

Virginia requires an initial in-person comprehensive work-up including physical examination, lab tests, and a documented lifestyle modification plan. The state also mandates a follow-up visit within 30 days of starting therapy and ongoing monitoring every few months.

States with Full Telehealth Freedom

Many states have embraced telehealth completely for weight loss medications:

California permits telehealth exams as sufficient for prescribing, with no in-person requirement. The state also grants nurse practitioners full independent practice authority after three years of experience, making access even easier.

Connecticut allows complete telehealth access but adds an important requirement: providers must include behavioral counseling and a documented diet/exercise plan as part of obesity treatment.

Florida permits telehealth prescribing without an in-person visit but imposes specific clinical criteria: patients must have a BMI of 30 or higher (or 27 with comorbidities) and must be seen at least once every three months during treatment.

Illinois, New York, and Pennsylvania all have permanent telehealth laws with no special restrictions on weight loss medication prescribing beyond standard medical practices.

Washington stands out as particularly telehealth-friendly, with full NP independent practice and robust consumer privacy protections under the My Health My Data Act.

Utah recently expanded NP autonomy and fully embraces telehealth for weight management, though guidelines recommend an initial comprehensive evaluation (which can be done virtually).

Who Can Prescribe Weight Loss Medications Via Telehealth?

The type of provider you see matters, and it varies by state.

Medical Doctors (MDs) and Doctors of Osteopathy (DOs)

All states allow licensed physicians to prescribe GLP-1 medications via telehealth, provided they’re licensed in the state where you physically reside during the appointment. This is straightforward—if your telehealth provider is a physician licensed in your state, you’re good to go.

Nurse Practitioners (NPs)

The landscape for NPs is more complex but increasingly favorable. As of December 2025, 34 states plus DC grant nurse practitioners full independent practice authority, meaning they can diagnose, treat, and prescribe medications without physician oversight (typically after gaining 2-3 years of supervised experience).

States with full NP independence include California, Washington, New York, Arizona, Connecticut, Utah, and Virginia (after experience requirements are met). This means you might see an NP for your entire telehealth weight loss journey without ever interacting with a physician—and that’s completely legitimate.

States with collaborative requirements include Texas, Florida, Pennsylvania, Georgia, Mississippi, and several others. In these states, NPs can still prescribe GLP-1 medications, but they must have a formal agreement with a supervising physician. From your perspective as a patient, this usually doesn’t affect your care experience—you’ll still meet with the NP, but there’s a physician overseeing the practice.

Physician Assistants (PAs)

PAs can prescribe weight loss medications in all states, but like NPs, they operate under varying levels of physician supervision depending on state law. Most states require PAs to have a supervising physician, though some states have moved toward more autonomous PA practice in recent years.

Important note: Klarity Health works exclusively with appropriately licensed and credentialed providers in each state we serve, so you can trust that your prescriber is legally authorized and qualified to treat you, whether they’re an MD, DO, NP, or PA.

The Telehealth Weight Loss Medication Process: What to Expect

Understanding the typical patient journey helps set realistic expectations and ensures you’re working with a legitimate provider.

Step 1: Medical Evaluation

Reputable telehealth services start with a comprehensive medical questionnaire covering:

• Current height and weight (to calculate BMI)
• Complete medical history including chronic conditions
• Current medications and allergies
• Previous weight loss attempts
• Family history of thyroid cancer or Multiple Endocrine Neoplasia type 2 (critical contraindications for GLP-1s)
• History of pancreatitis, gallbladder disease, or gastroparesis
• Mental health history
• Pregnancy status and family planning

This isn’t a formality—providers need this information to determine if GLP-1 medications are safe and appropriate for you.

Step 2: Live Video Consultation

Federal and state laws generally require a synchronous (real-time) video visit to establish a valid patient-provider relationship. During this appointment, your provider will:

• Review your medical history in detail
• Discuss your weight loss goals and previous efforts
• Explain how GLP-1 medications work
• Cover potential side effects (nausea, vomiting, diarrhea, constipation, potential gallstone risk)
• Review contraindications and warning signs
• Discuss the importance of lifestyle modifications alongside medication
• Obtain informed consent
• Answer your questions

Red flag: Be extremely cautious of any service that offers to prescribe these medications based solely on a questionnaire without a live video visit. This violates standard of care and state regulations in most jurisdictions.

Step 3: Clinical Qualification

To receive a prescription for weight loss medications, you generally need to meet FDA-approved criteria:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, sleep apnea, etc.)

Providers should also verify that you’ve attempted lifestyle modifications (diet and exercise) unless there are medical reasons why you cannot. These medications aren’t ‘quick fixes’—they’re adjuncts to comprehensive weight management.

Step 4: Prescription and Pharmacy

If you qualify and the provider determines treatment is appropriate, they’ll send an electronic prescription to your pharmacy of choice. All GLP-1 medications must be dispensed through licensed pharmacies—you cannot legally obtain them from the prescriber directly or from overseas suppliers.

Your provider will typically start with:

• Wegovy: Starting dose of 0.25mg weekly, with gradual increases
• Ozempic: 0.25mg weekly (though this is off-label for weight loss)
• Mounjaro/Zepbound: 2.5mg weekly starter dose

The initial prescription is often for 4 weeks to assess your tolerance and response.

Step 5: Ongoing Monitoring

This is where legitimate telehealth providers distinguish themselves. You’ll need:

• Follow-up visits (typically at 1 month, then every 2-3 months)
• Weight tracking to monitor progress
• Side effect assessment and dose adjustments
• Lab work as indicated (metabolic panel, kidney function, occasionally lipid panel or HbA1c)
• Lifestyle counseling to support diet and exercise changes

Some states mandate specific follow-up schedules. Florida requires at least one visit every three months. Virginia mandates a check-in within 30 days of starting treatment. These aren’t arbitrary rules—GLP-1 medications require monitoring to ensure safety and effectiveness.

Cost Considerations: Insurance vs. Cash Pay

The financial landscape for weight loss medications is evolving rapidly.

Insurance Coverage

Traditional insurance coverage for obesity medications has been limited, but this is changing:

• Medicare still doesn’t cover weight loss medications (only FDA-approved diabetes medications for diabetic patients)
• Many private insurers now cover Wegovy and Zepbound for obesity, though prior authorization is typically required
• Medicaid coverage varies significantly by state

When insurance does cover these medications, copays can range from $25 to $500 per month depending on your plan.

Cash Pay Options

If you’re paying out of pocket:

• Wegovy: $1,300-$1,600 per month retail
• Ozempic: $900-$1,000 per month retail
• Mounjaro/Zepbound: $1,000-$1,200 per month retail

Manufacturer savings programs can reduce these costs significantly for eligible patients. For example, Novo Nordisk offers a savings card that may reduce Wegovy to as low as $25 per fill for commercially insured patients.

Klarity Health accepts both insurance and cash pay, with transparent pricing so you know exactly what to expect. Many patients find our pricing competitive with (or better than) other telehealth weight loss services, especially when factoring in the quality of care and ongoing support.

The Compounding Controversy

You may have seen ads for ‘compounded semaglutide’ at much lower prices ($200-400/month). Here’s what you need to know:

In May 2025, the FDA banned most compounding of semaglutide for weight loss after determining the drug shortage had resolved. Previously, pharmacies were allowed to compound (custom-make) versions of semaglutide under a drug shortage exception. With that exception removed, it’s now illegal for most compounding pharmacies to make semaglutide products.

Some telehealth companies that relied on compounded versions had to shut down their programs or lay off staff. Others are exploring legal workarounds or alternative formulations, but the regulatory environment is scrutinizing these closely.

Bottom line: Stick with FDA-approved brand-name medications from licensed pharmacies. The small cost savings aren’t worth the legal and safety risks of compounded or overseas products.

Safety Red Flags: How to Spot Illegitimate Providers

The popularity of GLP-1 medications has unfortunately attracted some bad actors. Watch for these warning signs:

🚩 No live video visit required – If you can get a prescription with just a questionnaire, walk away.

🚩 Guaranteed prescription – Legitimate providers evaluate each patient individually. No one can guarantee you’ll qualify before assessing your case.

🚩 Compounded or ‘generic’ versions – There is no FDA-approved generic semaglutide or tirzepatide. Any such claims should raise immediate concerns.

🚩 No licensed provider review – You should always know who your prescriber is, what their credentials are, and confirm they’re licensed in your state.

🚩 No follow-up requirement – Responsible prescribing includes monitoring. If a service prescribes these medications without requiring follow-up visits, they’re not prioritizing your safety.

🚩 Overseas pharmacies – Your medication should come from a U.S.-licensed pharmacy. Products from Canada, India, or elsewhere may be counterfeit, contaminated, or improperly stored.

🚩 Pressure tactics – Be wary of services that use aggressive marketing, limited-time offers, or scare tactics to push you into starting treatment.

🚩 Lack of informed consent – You should receive clear information about side effects, contraindications, and the commitment required (these are chronic medications, not quick fixes).

Special Populations and Considerations

Patients with Diabetes

If you have type 2 diabetes, you’re in a unique position. Ozempic and Mounjaro are FDA-approved for diabetes management and may be covered by insurance for that indication. Your provider might prescribe these for blood sugar control with weight loss as a beneficial side effect.

Patients with Pre-Existing Conditions

Certain conditions require extra caution or may disqualify you from GLP-1 therapy:

• Personal or family history of medullary thyroid carcinoma or MEN2: These are absolute contraindications (the medications carry an FDA black box warning)
• History of pancreatitis: Relative contraindication—your provider will weigh risks carefully
• Severe gastroparesis: These medications slow gastric emptying, which can worsen this condition
• Active gallbladder disease: GLP-1s may increase gallstone risk
• Kidney disease: Requires dose adjustments and careful monitoring
• Pregnancy or planning pregnancy: Must discontinue at least 2 months before conception

Mental Health Considerations

While GLP-1 medications have shown benefits for many patients with depression (weight loss can improve mood), there have been rare reports of suicidal ideation in some patients. Your provider should screen for mental health concerns and monitor you throughout treatment.

The Future of Telehealth Weight Loss Treatment

The regulatory environment continues to evolve in patient-friendly directions:

Federal Developments

Congress is considering the TREATS Act (reintroduced October 2025), which would permanently authorize telehealth prescribing of controlled substances for substance use disorder and mental health treatment. While this doesn’t directly affect GLP-1s, it signals strong Congressional support for expanding telehealth access across medical specialties.

The DEA is expected to propose new permanent rules for telehealth controlled substance prescribing in 2026, potentially making some pandemic-era flexibilities permanent. Again, this won’t affect weight loss medications (which aren’t controlled), but it reflects the broader acceptance of telemedicine as standard care.

State Trends

Multiple states are considering legislation to:

• Expand nurse practitioner independent practice authority (bills pending in Mississippi, Pennsylvania, and others)
• Strengthen telehealth parity laws requiring insurers to cover telehealth at the same rates as in-person care
• Streamline interstate licensing through enhanced participation in licensure compacts

The overall trajectory is toward greater access with appropriate safety guardrails—good news for patients seeking convenient, quality care.

New Medications on the Horizon

The GLP-1 space continues to evolve. In addition to existing options, several new anti-obesity medications are in late-stage trials, including:

• Oral versions of semaglutide (Rybelsus is approved for diabetes; higher doses for obesity are in development)
• Triple-receptor agonists targeting even more metabolic pathways
• Combination therapies pairing GLP-1s with other mechanisms

As these reach market, expect telehealth to remain a primary access point, with regulations continuing to adapt.

How Klarity Health Approaches Weight Loss Treatment

At Klarity Health, we’ve designed our weight loss program to balance accessibility with clinical excellence:

Licensed providers in your state: We work exclusively with MDs, DOs, NPs, and PAs who are fully licensed and credentialed in the states where we practice. You’re always seeing someone legally authorized to treat you.

Comprehensive evaluation: Our intake process includes detailed medical history, live video consultation, and careful assessment of whether GLP-1 therapy is right for you. We won’t prescribe these medications if we don’t believe they’re appropriate for your situation.

Ongoing support: Weight loss is a journey, not a destination. We schedule regular follow-ups to monitor your progress, adjust dosing, manage side effects, and provide the lifestyle coaching that makes these medications truly effective.

Transparent pricing: Whether you’re using insurance or paying cash, we’re upfront about costs. No surprise bills, no hidden fees.

Both insurance and cash pay accepted: We work with major insurance plans and also offer competitive cash pay rates for those without coverage or who prefer not to use insurance.

Holistic approach: While medications like Wegovy and Mounjaro are powerful tools, we emphasize that they work best alongside nutrition counseling, physical activity, behavioral strategies, and ongoing support. Our providers help you develop sustainable habits for long-term success.

Frequently Asked Questions

Do I need to see a doctor in person before getting weight loss medication through telehealth?

In most states, no. Federal law doesn’t require an in-person visit for non-controlled medications like GLP-1s. However, a handful of states (Arkansas, Delaware, Georgia, Mississippi, New Jersey, North Dakota, South Carolina, Texas, and Virginia) have specific requirements for initial in-person exams or comprehensive evaluations. Klarity Health follows all state-specific requirements where we practice.

Can nurse practitioners prescribe Wegovy or Ozempic?

Yes, in all states. However, some states require nurse practitioners to have physician collaboration or supervision agreements. Klarity ensures all our NPs operate within their state’s legal framework, so you can receive care confidently regardless of which type of provider you see.

Will my insurance cover telehealth visits for weight loss medication?

Many insurance plans now cover telehealth visits at the same rate as in-person appointments. Coverage for the medications themselves (Wegovy, Mounjaro/Zepbound) varies—some plans cover them with prior authorization, while others don’t. We can help verify your benefits and assist with prior authorization when needed.

How long does it take to get a prescription?

If you qualify after your initial consultation, most patients receive their prescription the same day. The prescription is sent electronically to your pharmacy, though medication availability and insurance processing can sometimes add a few days before you can pick up your first fill.

What if I move to a different state during treatment?

Your provider must be licensed in the state where you’re physically located during telehealth visits. If you move, we’ll work to connect you with a provider licensed in your new state. Thanks to interstate licensure compacts, many of our providers are licensed in multiple states.

Are there any side effects I should be aware of?

The most common side effects of GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. These are usually mild to moderate and often improve over time. Starting at a low dose and increasing gradually (as your provider directs) helps minimize side effects. More serious but rare risks include pancreatitis, gallbladder problems, and changes in vision. Your provider will discuss all risks during your consultation and monitor you throughout treatment.

How much weight can I expect to lose?

Clinical trials show average weight loss of:

• Wegovy (semaglutide 2.4mg): 15-20% of body weight over 68 weeks
• Mounjaro/Zepbound (tirzepatide): 15-22% of body weight over 72 weeks

Individual results vary. These medications work best when combined with lifestyle modifications. Not everyone responds equally, and your provider will help set realistic expectations based on your unique situation.

Taking the Next Step

If you’re struggling with obesity and traditional diet and exercise haven’t been enough, telehealth access to GLP-1 medications could be a game-changer. These medications are proven effective, FDA-approved, and now more accessible than ever thanks to telemedicine.

The key is working with a legitimate, licensed provider who will take the time to evaluate your situation, prescribe appropriately, and support you throughout your weight loss journey.

Klarity Health makes it easy to get started: Our streamlined process connects you with experienced providers who understand weight management and can determine if medications like Wegovy, Ozempic, or Mounjaro are right for you. We handle the complexity of state regulations, insurance verification, and ongoing care coordination so you can focus on your health goals.

Ready to explore whether telehealth weight loss treatment is right for you? Book a consultation with Klarity Health today and take the first step toward a healthier future. Our providers are available across multiple states, accepting both insurance and cash pay, with transparent pricing and a commitment to evidence-based, patient-centered care.

This article is for informational purposes only and doesn’t constitute medical advice. Always consult with a licensed healthcare provider about your specific situation. Medication availability, insurance coverage, and state regulations are subject to change.

Research Currency Statement

Verified as of: December 17, 2025

DEA Rules Status: DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025. Non-controlled medications (like GLP-1 agonists) are not subject to the Ryan Haight Act’s in-person rule, so they can be prescribed via telehealth under federal law.

States Verified: AR, CA, CT, DE, FL, GA, IL, MS, NJ, NY, ND, PA, SC, TX, UT, VA, WA (as of Dec 2025)

Sources newer than 2024: 15 of 18 sources (most sources are 2024–2025; older sources used only for baseline context)

⚠️ Flagged for follow-up: Federal telehealth rules for controlled substances are temporary (set to expire 12/31/2025) – an additional extension or new rule is expected. State laws are constantly evolving; watch for any changes in 2026. Also, FDA oversight on compounded GLP-1 medications tightened in 2025 – ensure compliance with current FDA guidance.

Citations

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – Drug Enforcement Administration (DEA), November 15, 2024. www.dea.gov

2. COVID-era telehealth prescribing extended – Axios, November 18, 2024. www.axios.com

3. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 – McDermott Will & Emery, November 18, 2024. www.mwe.com

4. The Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs – Goodwin Procter LLP, March 27, 2024. www.goodwinlaw.com

5. Hims cuts 4% of workforce amid ban on weight loss drug copies – Reuters, May 30, 2025. www.reuters.com

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid